Sugi Predict

Sugi Predict / Compounds / SCHEMBL239666

SCHEMBL239666

SCHEMBL239666

O=[N+]([O-])c1cc(F)c(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.52
▸ ALDH1A1 P00352 6/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ TSHR P16473 2/20 0.48
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ TTR P02766 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ GPR35 Q9HC97 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8105000 0.86 CYP19A1 (0.44) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL9811597 0.86 ALDH1A1 (0.59) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL29739404 0.84 ALDH1A1 (0.59) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL22117921 0.84 GPR35 (0.48) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL717613 0.84 ALDH1A1 (0.59) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL12326844 0.84 ALDH1A1 (0.50) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL12325972 0.84 CYP19A1 (0.43) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL2383502 0.84 ALDH1A1 (0.50) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL29974850 0.84 ALDH1A1 (0.50) CYP19A1ALDH1A1HIF1ATSHRKMT2A
SCHEMBL964914 0.84 GPR35 (0.57) CYP19A1ALDH1A1HIF1ATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798091-A Preparation process of 3,4, 5-trifluoroaniline 江苏丰山生化科技有限公司 2025-04-11 — — CN claimed
CN-118637975-B Synthesis method of 3,4, 5-trifluoro-bromobenzene 山东国邦药业有限公司 2024-11-22 — — CN claimed
CN-118637975-A Synthesis method of 3,4, 5-trifluoro-bromobenzene 山东国邦药业有限公司 2024-09-13 — — CN claimed
CN-108947850-B Preparation method of 3,4, 5-trifluoroaniline 蚌埠中实化学技术有限公司 2021-05-18 — — CN claimed
CN-110498730-A A kind of synthetic method of 1,2,4- trifluoro-benzene ZHEJIANG LINJIANG CHEMICAL CO LTD 2019-11-26 — — CN claimed
CN-107311869-B The preparation method of 3,4,5- trifluoronitrobenzene 浙江解氏新材料股份有限公司 2019-11-08 — — CN claimed
CN-108947850-A A kind of preparation method of 3,4,5- trifluoromethyl aniline 蚌埠中实化学技术有限公司 2018-12-07 — — CN claimed
CN-107311869-A The preparation method of 3,4,5 trifluoronitrobenzenes 浙江解氏新材料股份有限公司 2017-11-03 — — CN claimed
WO-2015160562-A1 SULFONATION OF AROMATIC POLYMERS IN THE PRESENCE OF A POLYFLUORINATED BENZENE COMPOUND AS SWELLING AGENT ROHM AND HAAS COMPANY (US) 2015-10-22 — — WO claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
CN-101811973-A Method for synthesizing halogen aromatic amines by high-selectivity liquid phase hydrogenation under the condition of no solvent UNIV ZHEJIANG TECHNOLOGY 2010-08-25 — — CN claimed
US-20100105953-A1 Human Adam-10 Inhibitors SYMPHONY EVOLUTION, INC. (US) 2010-04-29 — — US claimed
EP-1461313-B1 HUMAN ADAM-10 INHIBITORS EXELIXIS INC (US) 2009-08-05 — — EP claimed
CN-100360525-C Novel oxazolidone derivative, its preparing method and use SHANGHAI MEDICINE INST CAS (CN) 2008-01-09 — — CN claimed
CN-101020628-A Preparation method of 2, 4-difluoro-3-hydroxybenzoic acid CHEN WEIDONG (CN) 2007-08-22 — — CN claimed
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma SYMPHONY EVOLUTION, INC. 2006-09-07 — — US claimed
CN-1749256-A One class Xin De oxazolidone derivative, Preparation Method And The Use SHANGHAI MEDICINE INST CAS (CN) 2006-03-22 — — CN claimed
US-20050227973-A1 Human adam-10 inhibitors EXELIXIS, INC. 2005-10-13 — — US claimed
WO-2004037765-A1 A PROCESS FOR THE PREPARATION OF 3,4,5-TRIFLUORONITROBENZENE DR. REDDY'S LABORATORIES LTD. (IN) 2004-05-06 — — WO claimed
CN-1090265-A The method for preparing trifluorobenzene derivatives CIBA GEIGY AG (CH) 1994-08-03 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227973-A1 Human adam-10 inhibitors ADAM10, ADAM12, ADAM9 CYP19A1 317/4885ALDH1A1 824/4885HIF1A 1566/4885
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma ADAM10, MMP20, MMP10 CYP19A1 174/4885ALDH1A1 312/4885HIF1A 258/4885
US-20100105953-A1 Human Adam-10 Inhibitors ADAM10, MMP20, ADAM9 CYP19A1 383/4885ALDH1A1 541/4885HIF1A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.